Scarica l'app Stockscreener
41.52
0.34%
0.14
Dopo l'orario di chiusura:
41.50
-0.02
-0.05%
Precedente Chiudi:
$41.38
Aprire:
$41.4
Volume 24 ore:
927.69K
Relative Volume:
1.22
Capitalizzazione di mercato:
$2.41B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
3.6549
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
-2.14%
1M Prestazione:
+13.07%
6M Prestazione:
+52.98%
1 anno Prestazione:
-4.99%
Intervallo 1D:
$41.01
$42.47
Intervallo di 1 settimana:
$39.71
$42.51
Portata 52W:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Confronta AGIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
41.52 | 2.34B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Why (AGIO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Agios Pharmaceuticals to Host Conference Call for Q3 2025 Financial Results and Business Highlights - Quiver Quantitative
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET - MarketScreener
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET - GlobeNewswire Inc.
Can Agios Pharmaceuticals Inc. stock deliver sustainable ROEPortfolio Update Summary & Daily Stock Momentum Reports - newser.com
What drives Agios Pharmaceuticals Inc stock priceGrowth vs. Value Investing & Free Wealth Planning Blueprints - earlytimes.in
Agios Q2 2025 slides: PYRUKYND sales jump 45% as thalassemia approval nears - Investing.com UK
Earnings call transcript: Agios Pharm Q2 2025 sees 45% revenue jump - Investing.com Canada
Will Agios Pharmaceuticals Inc. see short term momentumWeekly Profit Analysis & High Return Stock Watch Alerts - newser.com
How Agios Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Decliners & Expert Verified Stock Movement Alerts - newser.com
What to expect from Agios Pharmaceuticals Inc. in the next 30 days2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
Is Agios Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 Momentum & Low Risk Investment Opportunities - newser.com
Will Agios Pharmaceuticals Inc. continue its uptrendJuly 2025 Decliners & Weekly Top Performers Watchlists - newser.com
Has Agios Pharmaceuticals Inc. formed a bullish divergence2025 Year in Review & Daily Stock Trend Reports - newser.com
Why Agios Pharmaceuticals Inc. (8AP) stock gets analyst attentionJuly 2025 Retail & Risk Managed Investment Signals - newser.com
Zacks Research Issues Pessimistic Outlook for AGIO Earnings - MarketBeat
Will Agios Pharmaceuticals Inc. outperform the marketForecast Cut & AI Forecast for Swing Trade Picks - newser.com
Will Agios Pharmaceuticals Inc. (8AP) stock outperform Dow JonesPortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Analyzing recovery setups for Agios Pharmaceuticals Inc. investorsJuly 2025 Catalysts & Smart Allocation Stock Reports - newser.com
How to use a screener to detect Agios Pharmaceuticals Inc. breakoutsWeekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com
Using R and stats models for Agios Pharmaceuticals Inc. forecasting2025 Trading Volume Trends & Weekly High Return Stock Opportunities - newser.com
Relative strength of Agios Pharmaceuticals Inc. in sector analysisTrade Volume Report & Scalable Portfolio Growth Methods - newser.com
Leading vs lagging indicators on Agios Pharmaceuticals Inc. performanceWeekly Trade Review & Safe Entry Trade Signal Reports - newser.com
Agios Pharmaceuticals' (AGIO) Hold (C-) Rating Reiterated at Weiss Ratings - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Cut to "Strong Sell" at Zacks Research - MarketBeat
Agios Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Exploring a 14% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Will Agios Pharmaceuticals Inc. stock benefit from commodity prices2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - Eastern Progress
What momentum shifts mean for Agios Pharmaceuticals Inc.July 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Is Agios Pharmaceuticals Inc. reversing from oversold territoryQuarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com
Published on: 2025-10-02 19:48:50 - newser.com
Agios Pharmaceuticals Hits Day High with 9.64% Surge in Stock Price - Markets Mojo
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Agios Pharmaceuticals Inc Azioni (AGIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Scadden David | Director |
Oct 08 '25 |
Sale |
41.00 |
200 |
8,200 |
17,603 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):